Skip to content
Back to Blog
Bio
2026-09-297 min read9

AI Reads Your Dossier First — MFDS Expands Its AI Drug Review System to Biologics and Data-Submission Drugs in 2027, and How Pharma and Bio SMEs Should Prepare for AI Self-Check of Submissions

MFDS's AI drug review system will expand to biologics and data-submission drugs in 2027, and a pre-submission AI self-check tool is being developed alongside it. This guide explains how pharma and bio SMEs can prepare their dossiers to avoid costly deficiency rounds.

KITIM Consulting Team

MFDS's AI Drug Review System at a Glance

Korea's Ministry of Food and Drug Safety (MFDS) is building an AI drug review system that will take over parts of the approval review. A project task force launched in February 2026, and the program will receive KRW 22.3 billion over three years (2026–2028).

  • 2026: The rollout starts with generics. MFDS is building AI models for active pharmaceutical ingredient (API) specifications and bioequivalence review first, and automating routine, repetitive checks across 624 types of applications.
  • 2027: Under the MFDS 2027 budget proposal announced on September 1, 2026 (KRW 882.9 billion in total), the scope expands to biologics and data-submission drugs. Its core functions are summarizing and translating review documents, validating application materials, and automating repetitive tasks.
  • 2028: The system is planned to cover new drugs.
  • The February announcement named "incremental modified drugs" as the 2027 target, while the September budget proposal says "biologics and data-submission drugs." Incremental modified drugs fall under the data-submission category, so the two statements don't really conflict. Still, check MFDS's final announcements to confirm the actual scope and timing.

    What Matters for Companies: AI Self-Check Before Submission

    The most direct change for companies is an industry support tool. It is being developed alongside the review system so that applicants can check their submissions for format and requirement errors before filing.

    Deficiency letters often come from basic mistakes rather than scientific issues: missing forms, mismatched specifications, and numbers that disagree across modules. When AI catches these errors first, reviewers can focus on the substance. MFDS is also aiming for a review timeline of about 240 days, so each round of deficiency responses costs relatively more. A single round can delay approval by months, which puts both launch timelines and funding plans at risk.

    Machine-Readable Dossiers Get Through First

  • Structured data: Use consistent terminology, units, and study numbers across CTD modules, and follow standard templates. A figure in a Module 2 summary that doesn't match the Module 3 source data is exactly what AI will flag first.
  • Data integrity and version control: Make sure API specifications and certificates of analysis are current, and that every revision can be traced.
  • Translation quality: Figures and terms often drift from the source when data from overseas CROs and CMOs is summarized and translated. A shared glossary helps keep translations consistent.
  • Biologics-specific sections: Cell bank history, process validation, and comparability data are long and usually written by several teams. Assign an owner to each section and set up a cross-check procedure.
  • Readiness Checklist for Pharma and Bio SMEs

  • Start with products in your pipeline that are scheduled for submission in 2027–2028.
  • Tighten internal RA document management: templates, file naming rules, and cross-verification steps.
  • Watch for release dates and pilot participation opportunities for the self-check tool.
  • Look into related support, such as MFDS's new Global Drug Regulatory Review Technical Support program (KRW 4.8 billion).
  • A Word of Caution: AI Does Not Replace Judgment

    In the early stages, AI is an assistive tool, and reviewers still make the final call. Passing a self-check means your format is compliant. It does not prove your science is sound. Before uploading materials to the self-check tool, also read the relevant notices on how trade secrets and data security will be protected.

    How KITIM Supports Regulatory Readiness

    KITIM helps pharma and bio SMEs prepare for approval. We run pre-submission gap assessments, review consistency across CTD modules, and connect companies with government regulatory support programs. If you want to review your submission practices before AI review expands, contact the KITIM consulting team. We will propose practical steps that fit your products and timelines.

    AI Drug ReviewMFDS 2027 BudgetSubmission Self-CheckCTD DossierBiologics ApprovalData-Submission DrugsRegulatory Digital Transformation

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.